Kiltearn Partners LLP Sells 16,200 Shares of Medtronic PLC $MDT

Kiltearn Partners LLP lessened its holdings in Medtronic PLC (NYSE:MDT) by 7.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 216,561 shares of the medical technology company’s stock after selling 16,200 shares during the period. Medtronic makes up 4.1% of Kiltearn Partners LLP’s portfolio, making the stock its 8th biggest position. Kiltearn Partners LLP’s holdings in Medtronic were worth $20,625,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in MDT. Artisan Partners Limited Partnership lifted its stake in Medtronic by 2.6% during the third quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock worth $117,579,000 after purchasing an additional 31,314 shares during the period. AXQ Capital LP boosted its holdings in Medtronic by 25.6% during the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock valued at $862,000 after purchasing an additional 2,013 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock valued at $13,170,000 after purchasing an additional 54,898 shares during the period. Applied Finance Capital Management LLC acquired a new position in shares of Medtronic in the 3rd quarter worth approximately $1,308,000. Finally, Willis Investment Counsel raised its holdings in shares of Medtronic by 5.0% in the 3rd quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock worth $38,274,000 after buying an additional 19,192 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Trading Down 2.3%

Shares of MDT opened at $90.83 on Monday. The stock has a fifty day moving average price of $98.69 and a two-hundred day moving average price of $97.02. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54. Medtronic PLC has a 52-week low of $79.55 and a 52-week high of $106.33. The company has a market cap of $116.61 billion, a price-to-earnings ratio of 25.30, a PEG ratio of 2.28 and a beta of 0.71.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts predict that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic’s dividend payout ratio is 79.11%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved quarterly cash dividend of $0.71 per share (annualized yield ~3.1%), supporting income investors and signaling confidence in cash flow. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Product/market progress in diabetes care with the MiniMed Go Smart MDI system launch in Europe, strengthening Medtronic’s connected diabetes portfolio and long‑term growth potential in CGM/smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Operational tech wins: updates on a Tempus clinical trial and expanded patient‑monitoring alliance with GE HealthCare, which could broaden distribution and adoption of Medtronic devices over time. Digital Alerts and Heart Valves: What Medtronic Investors Should Watch in New Tempus Trial Medtronic, GE HealthCare expand patient monitoring alliance
• Neutral Sentiment: MiniMed priced its IPO at $20 per share and raised about $560M, giving the standalone diabetes unit initial capital and a public valuation backdrop. This is a financing/structuring move that could be positive long term but is mixed near term. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO
• Negative Sentiment: MiniMed’s Nasdaq debut opened below the offering price (shares down ~4.8% on debut), which pressured sentiment toward the spinoff and Medtronic’s value‑unlock story — investors reacted to a softer than expected market reception. Medtronic’s diabetes unit MiniMed valued at $5.3 billion as shares fall in Nasdaq debut
• Negative Sentiment: Medtronic retains ~90% ownership of MiniMed after the IPO, limiting immediate capital release and potential near‑term accretion from the spinoff — this reduces the perceived benefit of the listing for MDT shareholders today. MiniMed (MMED) IPO Falls Flat as Medtronic (MDT) Spinoff Debuts Below Price

Wall Street Analyst Weigh In

Several analysts recently commented on MDT shares. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research note on Friday, November 14th. CICC Research assumed coverage on Medtronic in a research note on Friday, January 30th. They set an “outperform” rating for the company. Mizuho raised Medtronic to a “strong-buy” rating in a report on Wednesday, February 18th. Jefferies Financial Group restated a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research note on Wednesday, November 19th. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).